Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan

Despite ‘tension’ between two industries over what is required to show generic is no less abuse-deterrent than innovator opioid, FDA’s Throckmorton suggests they come up with single approach to product development.

pills

FDA is encouraging the brand and generic drug industries to come up with a unified proposal for the development of generic abuse-deterrent opioid products.

Douglas Throckmorton, deputy director for regulatory programs in FDA’s Center for Drug Evaluation and Research, advocated the approach at the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics